Table 2. Demographic and clinical characteristics of the study patients stratified by changes in cyst size during the follow-up period.
| Variable | Group A (stable cyst size) | Group B (changed cyst size) | p-value |
|---|---|---|---|
| Age (y), median (range) | 68.5 (38-89) | 66 (52-75) | 0.85 |
| Sex | 0.76 | ||
| Male | 31 | 5 | |
| Female | 23 | 5 | |
| Primary tumors | 0.65 | ||
| Colon cancer | 47 | 8 | |
| Breast cancer | 2 | 1 | |
| Lung cancer | 4 | 1 | |
| Ovarian cancer | 1 | - | |
| Average does of bevacizumab (mg/kg/wk) | 2.61 | 2.75 | 0.96 |
| 5 mg/kg every 2 weeks (n) | 33 | 8 | |
| 7.5 mg/kg every 2 weeks (n) | 18 | - | |
| 10 mg/kg every 3 weeks (n) | 1 | - | |
| 15 mg/kg every 3 weeks (n) | 2 | 1 | |
| Duration of bevacizumab therapy (wk), median (range) | 29 (8-104) | 62 (30-93) | <0.0002 |